We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can UNH's Optum Rx Sustain Profit Growth as Prescription Volumes Fall?
Read MoreHide Full Article
Key Takeaways
UNH's Optum Rx earnings rose 10.9% to $1.72 billion despite a 5.1% drop in adjusted prescriptions.
Optum Rx's margin widened to 4.3% from 3.9%, supported by biosimilar adoption and operating efficiencies.
Optum Rx's specialty volumes rose 2.6%, but membership losses and pricing changes pose challenges.
UnitedHealth Group Incorporated’s (UNH - Free Report) Optum Rx delivered higher operating earnings despite declining prescription volumes in the third quarter of 2026. Stronger profitability, supported by biosimilar adoption and operational efficiencies, highlights the segment's resilience amid membership-related pressures. However, sustaining this momentum without a recovery in prescription activity remains a key challenge.
Optum Rx revenues edged up to $39.9 billion from $39.7 billion a year earlier. Operating earnings increased 10.9% to $1.72 billion, expanding the operating margin to 4.3% from 3.9%. Adjusted prescriptions declined 5.1% to 393 million, reflecting membership losses at UnitedHealthcare and other customers. The contrasting trends suggest that improving operating performance is helping offset weaker prescription activity.
Specialty pharmacy offers an additional growth opportunity. Management reported a 2.6% increase in specialty volumes during the quarter, supported by strong demand for complex therapies and expanding provider relationships. Optum Rx is also strengthening its integrated pharmacy services, including infusion offerings, while advancing transparent pharmacy benefit pricing. These initiatives could support customer retention, improve business mix and provide additional earnings opportunities.
Nevertheless, continued membership attrition could restrict overall prescription growth, while evolving pharmacy pricing arrangements may influence future profitability. Sustained margin expansion will require disciplined cost management and successful execution of higher-value pharmacy services. Although the segment has demonstrated its ability to improve profitability amid softer volumes, a recovery in prescription activity would provide a more durable foundation for earnings growth through 2027.
How Are UNH's Peers Positioned?
UnitedHealth's Medical sector peers, The Cigna Group (CI - Free Report) and CVS Health Corporation (CVS - Free Report) , also illustrate how business mix and operating discipline affect profitability.
Cigna's Evernorth reported 6% growth in adjusted revenues in the third quarter of 2026, but adjusted pretax operating earnings declined 4%. Cigna’s Pharmacy Benefit Services earnings fell 22%, while Specialty and Care Services earnings rose 15%, partly reflecting biosimilar and specialty generic adoption.
CVS's Health Services segment reported 9.5% revenue growth and a 2.7% increase in adjusted operating income during the quarter. Pharmacy claims processed increased 1.3% on a 30-day equivalent basis. Unlike Optum Rx, CVS reported volume growth, underscoring different operating dynamics across the industry.
UNH’sPrice Performance, Valuation & Estimates
Shares of UnitedHealth have risen 22.8% year to date compared with the industry’s 25.7% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, UNH trades at a forward price-to-earnings ratio of 17.6 compared with the industry average of 15.68. UNH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $20.61 per share, implying a 20.06% increase from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Bigstock
Can UNH's Optum Rx Sustain Profit Growth as Prescription Volumes Fall?
Key Takeaways
UnitedHealth Group Incorporated’s (UNH - Free Report) Optum Rx delivered higher operating earnings despite declining prescription volumes in the third quarter of 2026. Stronger profitability, supported by biosimilar adoption and operational efficiencies, highlights the segment's resilience amid membership-related pressures. However, sustaining this momentum without a recovery in prescription activity remains a key challenge.
Optum Rx revenues edged up to $39.9 billion from $39.7 billion a year earlier. Operating earnings increased 10.9% to $1.72 billion, expanding the operating margin to 4.3% from 3.9%. Adjusted prescriptions declined 5.1% to 393 million, reflecting membership losses at UnitedHealthcare and other customers. The contrasting trends suggest that improving operating performance is helping offset weaker prescription activity.
Specialty pharmacy offers an additional growth opportunity. Management reported a 2.6% increase in specialty volumes during the quarter, supported by strong demand for complex therapies and expanding provider relationships. Optum Rx is also strengthening its integrated pharmacy services, including infusion offerings, while advancing transparent pharmacy benefit pricing. These initiatives could support customer retention, improve business mix and provide additional earnings opportunities.
Nevertheless, continued membership attrition could restrict overall prescription growth, while evolving pharmacy pricing arrangements may influence future profitability. Sustained margin expansion will require disciplined cost management and successful execution of higher-value pharmacy services. Although the segment has demonstrated its ability to improve profitability amid softer volumes, a recovery in prescription activity would provide a more durable foundation for earnings growth through 2027.
How Are UNH's Peers Positioned?
UnitedHealth's Medical sector peers, The Cigna Group (CI - Free Report) and CVS Health Corporation (CVS - Free Report) , also illustrate how business mix and operating discipline affect profitability.
Cigna's Evernorth reported 6% growth in adjusted revenues in the third quarter of 2026, but adjusted pretax operating earnings declined 4%. Cigna’s Pharmacy Benefit Services earnings fell 22%, while Specialty and Care Services earnings rose 15%, partly reflecting biosimilar and specialty generic adoption.
CVS's Health Services segment reported 9.5% revenue growth and a 2.7% increase in adjusted operating income during the quarter. Pharmacy claims processed increased 1.3% on a 30-day equivalent basis. Unlike Optum Rx, CVS reported volume growth, underscoring different operating dynamics across the industry.
UNH’sPrice Performance, Valuation & Estimates
Shares of UnitedHealth have risen 22.8% year to date compared with the industry’s 25.7% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, UNH trades at a forward price-to-earnings ratio of 17.6 compared with the industry average of 15.68. UNH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $20.61 per share, implying a 20.06% increase from the year-ago period’s level.
Image Source: Zacks Investment Research
UNH currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.